Literature DB >> 6416608

A study of inactivation of Chlamydia trachomatis by normal human serum.

A P Johnson, M F Osborn, S Rowntree, B J Thomas, D Taylor-Robinson.   

Abstract

To assess the effect of human serum on the viability of Chlamydia trachomatis, organisms were mixed with unheated and heat inactivated homologous serum, and the numbers surviving after incubation at 37 degrees C for 1 hour were compared. With a pool of sera obtained from 12 donors, the number of chlamydiae surviving incubation in unheated serum was less than 1% of that surviving incubation in heat inactivated serum. The antichlamydial activity of the unheated pooled serum samples could be noticeably reduced by treatment with Mg-EGTA (ethyleneglycolbis (beta-amino ethyl ether)-N,N'-tetra-acetic acid). This indicated a requirement for calcium ions and showed that the alternative pathway of complement activation played only a minor role, if any, in the inactivation process. When 12 serum samples were tested individually it was found that four inactivated chlamydiae to an extent comparable with that seen with the pooled serum. The other eight samples showed only moderate (or slight) antichlamydial activity, with survival rates in unheated serum of 20-60% (or more than 60%) of those in heat inactivated serum. There was no correlation between the titres of antichlamydial antibodies and antichlamydial activity, all serum samples having undetectable or low concentrations of antibody on measurement by micro-immunofluorescence. The antichlamydial activity destroyed by heating was restored, however, when heat inactivated serum was mixed with an equal volume of an unheated serum that was not inhibitory to chlamydiae. When the latter serum was heated before addition antichlamydial activity was not restored, indicating the requirement of both a heat stable and a heat labile factor. This observation and the need for calcium ions for inactivation of chlamydiae are compatable with killing mediated by antibody and complement. Thus serum samples from individuals with no clinical or serological evidence of infection with chlamydiae vary in their ability to inactivate the organism, some having antichlamydial activity which is possibly mediated by antibody and complement.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6416608      PMCID: PMC1046239          DOI: 10.1136/sti.59.6.369

Source DB:  PubMed          Journal:  Br J Vener Dis        ISSN: 0007-134X


  9 in total

1.  The surface properties of Neisseria gonorrhoeae: determinants of susceptibility to antibody complement killing.

Authors:  M E Ward; P R Lambden; J E Heckels; P J Watt
Journal:  J Gen Microbiol       Date:  1978-10

2.  Simplified serological test for antibodies to Chlamydia trachomatis.

Authors:  B J Thomas; P Reeve; J D Oriel
Journal:  J Clin Microbiol       Date:  1976-07       Impact factor: 5.948

Review 3.  Microbial surfaces in relation to pathogenicity.

Authors:  H Smith
Journal:  Bacteriol Rev       Date:  1977-06

Review 4.  Chlamydiae.

Authors:  J Schachter; H D Caldwell
Journal:  Annu Rev Microbiol       Date:  1980       Impact factor: 15.500

Review 5.  The rôle of Chlamydia trachomatis in genital-tract and associated diseases.

Authors:  D Taylor-Robinson; B J Thomas
Journal:  J Clin Pathol       Date:  1980-03       Impact factor: 3.411

6.  Early detection of chlamydial inclusions combining the use of cycloheximide-treated McCoy cells and immunofluorescence staining.

Authors:  B J Thomas; R T Evans; G R Hutchinson; D Taylor-Robinson
Journal:  J Clin Microbiol       Date:  1977-09       Impact factor: 5.948

7.  C3 shunt activation in human serum chelated with EGTA.

Authors:  D P Fine; S R Marney; D G Colley; J S Sergent; R M Des Prez
Journal:  J Immunol       Date:  1972-10       Impact factor: 5.422

8.  Analysis of the human serological response to proteins of Chlamydia trachomatis.

Authors:  W J Newhall; B Batteiger; R B Jones
Journal:  Infect Immun       Date:  1982-12       Impact factor: 3.441

9.  Bactericidal activity of the alternative complement pathway generated from 11 isolated plasma proteins.

Authors:  R D Schreiber; D C Morrison; E R Podack; H J Müller-Eberhard
Journal:  J Exp Med       Date:  1979-04-01       Impact factor: 14.307

  9 in total
  7 in total

1.  Early complement components enhance neutralization of Chlamydia trachomatis infectivity by human sera.

Authors:  J S Lin; L L Yan; Y Ho; P A Rice
Journal:  Infect Immun       Date:  1992-06       Impact factor: 3.441

2.  Susceptibility of different serovars of Chlamydia trachomatis to inactivation by normal human serum.

Authors:  M F Osborn; A P Johnson; D Taylor-Robinson
Journal:  Genitourin Med       Date:  1985-08

3.  Characterization of kinetics and target proteins for binding of human complement component C3 to the surface-exposed outer membrane of Chlamydia trachomatis serovar L2.

Authors:  R T Hall; T Strugnell; X Wu; D V Devine; H G Stiver
Journal:  Infect Immun       Date:  1993-05       Impact factor: 3.441

4.  Neutralization of Chlamydia trachomatis: kinetics and stoichiometry.

Authors:  R W Peeling; R C Brunham
Journal:  Infect Immun       Date:  1991-08       Impact factor: 3.441

5.  Cytotoxic and immunoregulatory function of intestinal lymphocytes in Chlamydia trachomatis proctitis of nonhuman primates.

Authors:  S P James; A S Graeff; M Zeitz; E Kappus; T C Quinn
Journal:  Infect Immun       Date:  1987-05       Impact factor: 3.441

6.  Complement and Chlamydia psittaci: Early Complement-Dependent Events Are Important for DC Migration and Protection During Mouse Lung Infection.

Authors:  Martin Kohn; Christian Lanfermann; Robert Laudeley; Silke Glage; Claudia Rheinheimer; Andreas Klos
Journal:  Front Immunol       Date:  2021-03-09       Impact factor: 7.561

Review 7.  An Ancient Molecular Arms Race: Chlamydia vs. Membrane Attack Complex/Perforin (MACPF) Domain Proteins.

Authors:  Gabrielle Keb; Kenneth A Fields
Journal:  Front Immunol       Date:  2020-07-14       Impact factor: 7.561

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.